The company said full-year 2024 revenue was $2,071.6 million, up 22.1% from $1,697.1 million a year earlier, or 21.9% in constant currency. That was above its constant currency guidance range of 20% to 21%.

1. 01

   The company said full-year 2024 revenue was $2,071.6 million, up 22.1% from $1,697.1 million a year earlier, or 21.9% in constant currency. That was above its constant currency guidance range of 20% to 21%.

2. 02

   Insulet said revenue for Q4 2024 was $597.5 million, up 17.2% (17.1% in constant currency), and U.S. Omnipod revenue was $443.7 million, up 12.4%. The company said stocking dynamics in Q4 of the prior year had an impact of about 1,100 basis points on U.S. Omnipod revenue growth.

3. 03

   Insulet reported full-year 2024 operating income of $308.9 million (14.9% of revenue) and net income of $418.3 million, or $5.78 per diluted share. The company said adjusted net income, which excludes a tax benefit of $190.8 million primarily tied to the release of its valuation allowance, was $230.4 million.

4. 04

   Insulet said operating cash flow for full-year 2024 was $430.3 million, compared with $145.7 million a year earlier, and free cash flow was $305.4 million, compared with $70.1 million. The company also said it had cash and cash equivalents of $953.4 million as of December 31, 2024.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.